NEW YORK (360Dx) – Hardy Diagnostics said on Friday it has become an authorized distributor of EliTechGroup's Mycofast US, a system for detecting, enumerating, and identifying genital Mycoplasma hominis and Ureaplasma urealyticum.
Financial and other terms of the deal were not disclosed.
According to EliTechGroup's website, Mycofast US can detect urogenital mycoplasma in endocervical, urethral, urinary, gastric and sperm specimens. Because it leverages a visual colorimetric method expert interpretation is not required, the company said. Positive test results can be attained in 24 hours, and negative test results are available in 48 hours.
"This is a streamlined version of the traditional culture media method with enhanced sensitivity," Hardy Dx said in a statement, adding that while molecular methods are faster, "the nature of this kind of diagnosis is seldom urgent." As a result, Mycofast US is a cost-effective alternative to traditional culture media and PCR methods.
Based in Santa Maria, California, Hardy manufactures and distributes medical devices with a focus on the microbiology space. EliTechGroup is an in vitro diagnostics specialty company based in Puteaux, France.